298 related articles for article (PubMed ID: 27602187)
1. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
Al Musalhi K; Al Kindi M; Al Aisary F; Ramadhan F; Al Rawahi T; Al Hatali K; Mula-Abed WA
Oman Med J; 2016 Sep; 31(5):336-44. PubMed ID: 27602187
[TBL] [Abstract][Full Text] [Related]
2. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
4. RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study.
Liest AL; Omran AS; Mikiver R; Rosenberg P; Uppugunduri S
Acta Obstet Gynecol Scand; 2019 Jan; 98(1):24-33. PubMed ID: 30216407
[TBL] [Abstract][Full Text] [Related]
5. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
Davenport C; Rai N; Sharma P; Deeks JJ; Berhane S; Mallett S; Saha P; Champaneria R; Bayliss SE; Snell KI; Sundar S
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011964. PubMed ID: 35879201
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
7. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
[TBL] [Abstract][Full Text] [Related]
8. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.
Janas L; Stachowiak G; Glowacka E; Piwowarczyk I; Kajdos M; Soja M; Masternak M; Nowak M
Ginekol Pol; 2023 Jan; ():. PubMed ID: 36597746
[TBL] [Abstract][Full Text] [Related]
9. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
10. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
11. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
12. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
Winarto H; Laihad BJ; Nuranna L
Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
14. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
15. Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer.
Al-Musalhi K; Al-Kindi M; Ramadhan F; Al-Rawahi T; Al-Hatali K; Mula-Abed WA
Oman Med J; 2015 Nov; 30(6):428-34. PubMed ID: 26675326
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
[TBL] [Abstract][Full Text] [Related]
17. [Ovarian tumor markers of presumed benign ovarian tumors].
Lahlou N; Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
[TBL] [Abstract][Full Text] [Related]
18. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
19. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam.
Huy NVQ; Van Khoa V; Tam LM; Vinh TQ; Tung NS; Thanh CN; Chuang L
Gynecol Oncol Rep; 2018 Aug; 25():110-114. PubMed ID: 30109256
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]